Obesity drug dropped as 'too risky'

GPs warn treatment options should not be limited where a benefit is shown.

Dr Haslam: 'benefits lost'
Dr Haslam: 'benefits lost'

GPs have expressed disappointment at the suspension of the weight-loss drug rimonabant.

Dr Ian Campbell, a GP in Nottingham and medical director of the charity Weight Concern, said prescribers are aware of the drug's adverse effects on anxiety and depression and monitored patients closely.

'It is disappointing for those patients for whom the drug is working,' he said.

Around 20,000 patients in the UK have been treated with rimonabant, marketed as Acomplia, but last week the European Medicines Agency (EMEA) decided that its benefits no longer outweigh its risks.

Prescribers should not issue any new prescriptions for the drug, the EMEA said.

Patients do not need to stop treatment immediately, but those who wish to stop can do so at any time, the EMEA advised.

Dr David Haslam, a GP in Hertfordshire and clinical director of the National Obesity Forum, said the move was 'a great shame'.

'I have patients whose diabetes is well controlled who have benefited from rimonabant and that benefit will end when their treatment ends.'

The drug's manufacturer Sanofi-Aventis said it was complying with the EMEA's recommendation and would provide additional evidence for re-evaluation of the drug's benefit-risk profile in patients with diabetes and cardiovascular disease.

The EMEA said its assessment showed an increased risk of psychiatric disorders in patients taking rimonabant. In addition, the agency said that the drug's effectiveness in clinical practice had been found to be more limited than was expected.

Sir Michael Rawlins, chairman of NICE, told GP that the institute had withdrawn its June guidance, which recommended the drug for third-line use after orlistat and sibutramine.

tom.moberly@haymarket.com.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Government must show evidence behind PPE strategy, warns BMA

Government must show evidence behind PPE strategy, warns BMA

Chronic shortages of personal protective equipment (PPE) across the NHS during the...

Viewpoint: Bullying is a silent epidemic within the NHS

Viewpoint: Bullying is a silent epidemic within the NHS

There is a lack of training in general practice around understanding bullying, says...

HRT prescriptions lower in most deprived areas of England, study finds

HRT prescriptions lower in most deprived areas of England, study finds

Prescriptions for HRT are 29% lower in GP practices in England's most deprived areas...

Map: Which parts of England are most reliant on GPs aged over 55?

Map: Which parts of England are most reliant on GPs aged over 55?

More than two-fifths of the full-time equivalent (FTE) GP workforce is aged over...

Government outlines PPE supply plans as GPs remain in dark over reimbursement

Government outlines PPE supply plans as GPs remain in dark over reimbursement

The government has outlined plans to provide 'an uninterrupted supply' of PPE during...

Four in five GPs report heavy workload as COVID-19 second wave builds

Four in five GPs report heavy workload as COVID-19 second wave builds

Four in five GPs say their practice is currently facing levels of workload that are...